Determinants of endothelial function in a cohort of patients with peripheral artery disease

Cardiology

Volumn 111, Issue 1, 2008, Pages 51-56

  Golledge, J ^a,b   Leicht, A S ^a   Crowther, R G ^a   Glanville, S ^b   Clancy, P ^a   Sangla, K S ^b   Spinks, W L ^a   Quigley, F ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Endothelial function; Metabolic syndrome; Obesity; Osteoprotegerin; Peripheral artery disease

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; LEPTIN; OSTEOPROTEGERIN; RESISTIN;

ADULT; ARTERY DISEASE; ARTERY ENDOTHELIUM; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

ADIPOSITY; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; VASODILATION;

EID: 48249102696     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113428     Document Type: Article

References (30)

1. Simionescu M: Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 2007;27:266-274.
2. Koenig W, Khuseyinova N: Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26.
3. Raitakari OT, Celermajer DS: Flow-mediated dilatation. Br J Clin Pharmacol 2000;50:397-404.
4. Hashimoto M, Miyamoto Y, Matsuda Y, Akita H: New methods to evaluate endothelial function: non-invasive method of evaluating endothelial function in humans. J Pharmacol Sci 2003;93:405-408.
5. Karatzis EN, Ikonomidis I, Vamvakou GD, Papaioannou TG, Protogerou AD, Andreadou I, et al: Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol 2006;98:1424-1428.
6. Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY: A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 2003;14:425-431.
7. Yu HI, Sheu WH, Lai CJ, Lee WJ, Chen YT: Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease. Int J Cardiol 2001;78:19-25.
8. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA: Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-1775.
9. Golledge J, Leicht A, Crowther RG, Clancy P, Spinks WL, Quigley F: Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J Vasc Surg 2007;45:40-46.
10. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
11. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
12. 12, MTHFR genotypes, and plasma homocysteine. Clin Chem 2006;52:1205-1206.
13. Clancy P, Oliver L, Jayalath R, Buttner P, Golledge J: Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol 2006;26:2574-2576.
14. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-2180.
15. Ziegler S, Kudlacek S, Luger A, Minar E: Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005;182:175-180.
16. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr, Lehman BT, Fan S, Osypiuk E, Vita JA: Clinical correlates and heritability of flow-mediated dilation in the community: The Framingham Heart Study. Circulation 2004;109:613-619.
17. Thomas GN, Chook P, Qiao M, Huang XS, Leong HC, Celermajer DS, et al: Deleterious impact of 'high normal' glucose levels and other metabolic syndrome components on arterial endothelial function and intimamedia thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004;24:739-743.
18. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM: Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005;258:250-256.
19. Hsueh WA, Lyon CJ, Quinones MJ: Insulin resistance and the endothelium. Am J Med 2004;117:109-117.
20. Han SH, Quon MJ, Koh KK: Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007;18:58-65.
21. Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, et al: Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005;181:321-327.
22. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C: Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res 2005;126:121-129.
23. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL, et al: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006;113:2113-2119.
24. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS: Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454-5461.
25. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47:1850-1857.
26. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-1194.
27. Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH, et al: Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005;54:49-54.
28. Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S: Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006;64:652-658.
29. Brandstrom H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A: A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 2002;293:13-17.
30. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, et al: An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006;169:2236-2244.